On the other hand, leniolisib (CDZ173), a potent and selective oral inhibitor of PI3Kdelta (128), has been successfully used in a series of patients with APDS, in which PI3Kdelta gain-of-function mutation results in lymphoproliferation of the MALT, T-cell senescence and immunodeficiency. This evidence concerns the gene PIK3CD and immunodeficiency disease.